Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.78 |
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.61 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.61 |
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.49 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.48 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.78 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.78 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL659782 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL38685 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL6850585 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL29728780 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4538254 | 0.98 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4950608 | 0.98 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL29466902 | 0.98 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL1059266 | 0.98 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hoechst 33258 SCHEMBL6942659 | 0.95 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL15969230 | 0.93 | ALDH1A1 (0.90) | ALDH1A1SMN1; SMN2MAPTMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250332270-A1 | Targeting Skin-Related Conditions Using Bottlebrush Polymer-Conjugated Oligonucleotides | UNIV NORTHEASTERN (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4554576-A2 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | University of Southern California (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-118340895-A | Application of CDC123 as target in preparation of medicine for preventing and/or treating colon cancer | 浙江大学 | 2024-07-16 | — | — | CN | disclosed |
| WO-2024015963-A2 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-115340571-A | Novel artemisinin derivatives, preparation method of liposome and application of liposome | 中国中医科学院中药研究所 | 2022-11-15 | — | — | CN | disclosed |
| WO-2021045890-A1 | CELLULAR POTASSIUM IMAGING USING A RATIOMETRIC FLUORESCENT SENSOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-3223816-B1 | METHODS FOR TREATING A CYTOMEGALOVIRUS INFECTION | THE J DAVID GLADSTONE INST (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10478431-B2 | Methods for treating a cytomegalovirus infection | THE J. DAVID GLADSTONE INSTITUTES (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190111181-A1 | METHODS FOR DENUCLEATION OF BIOLOGICAL TISSUE | KASSAB GHASSAN S (US) | 2019-04-18 | — | — | US | disclosed |
| US-20170360778-A1 | Methods for Treating a Cytomegalovirus Infection | THE J. DAVID GLADSTONE INSTITUTES | 2017-12-21 | — | — | US | disclosed |
| WO-2017021177-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITAT DE BARCELONA (ES) | 2017-02-09 | — | — | WO | disclosed |
| WO-2013169793-A2 | METHODS AND COMPOSITIONS FOR TDP-43 PROTEINOPATHIES | IPIERIAN, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10478431-B2 | Methods for treating a cytomegalovirus infection | MGMT, CMBL, PAICS | GLA 1809/4885TOP1 210/4885TOP2A 295/4885 |
| US-20250388597-A1 | BIFUNCTIONAL PHOTOCROSSLINKING PROBES FOR COVALENT CAPTURE OF PROTEIN-NUCLEIC ACID COMPLEXES IN CELLS | PCNA, DDB1, DCLRE1A | GLA 3472/4885TOP1 36/4885TOP2A 102/4885 |
| US-20170360778-A1 | Methods for Treating a Cytomegalovirus Infection | MGMT, CMBL, PAICS | GLA 1809/4885TOP1 210/4885TOP2A 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.